Stock PHVS PHARVARIS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

All News Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
18.96 USD +0.32% Intraday chart for Pharvaris N.V. -6.05% -32.41%
May. 09 Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating MT
May. 08 Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pharvaris N : Development of Kallikrein Kinin System Biomarker Assays to Investigate Bradykinin mediated Diseases
PU
Pharvaris N : Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema
PU
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
GL
Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating
MT
Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024
CI
Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating
MT
Pharvaris Files Mixed Shelf
MT
Pharvaris Narrows Q4 Net Loss; Hires New CFO
MT
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
GL
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
CI
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
GL
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
GL
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
AQ
Pharvaris N : Poster
PU
Pharvaris N : EGM Meeting Minutes
PU
Pharvaris N : Results of Extraordinary General Meeting of Shareholders - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHVS Stock
  4. News Pharvaris N.V.